Fibromyalgia News and Research

Latest Fibromyalgia News and Research

Latest achievements in brain research and treatment for mental disorders

Mental disorders, such as depression, anxiety disorders, addiction and schizophrenia are the core challenge of most health care systems around the world. In the EU alone, each year 27% of the total adult population - this corresponds to 83 Million citizens - suffer from mental disorders. Depression alone affects almost 20 million ranking in the EU as the most disabling disorder of all diseases.

30 Aug 2010

23rd European College of Neuropsychopharmacology Congress to be held 28 Aug - 1 Sep 2010 in Amsterdam

26 Aug 2010

Vitamin D2 in AbM mushroom can neutralize oxidative stress: Research

Total Nutraceutical Solutions, Inc., announced that it has completed a research study comparing the therapeutic effect of single nutrient forms of synthetic Vitamin D3 and D2 versus natural Vitamin D2 within a whole food. The study focused on the control of Paraquat induced oxidative stress/biologic death.

25 Aug 2010

National Fibromyalgia Association, RemedyMD partner to build fibromyalgia research registry

The National Fibromyalgia Association has partnered with RemedyMD® to provide a national database that will aggregate data from a wide variety of sources to provide a complete disease registry for fibromyalgia research. It offers new hope to sufferers since this will represent the first time that researchers have the opportunity to look at all data relevant to fibromyalgia in order to identify patterns which lead to more effective diagnosis and treatment.

24 Aug 2010

Jazz Pharmaceuticals disappointed with FDA Advisory Committee recommendation for JZP-6 in fibromyalgia

Jazz Pharmaceuticals, Inc. announced that the Joint Advisory Committee of the U.S. Food and Drug Administration (FDA), including the Arthritis Advisory Committee and the Drug Safety and Risk Management Advisory Committee, voted 20-2 that the benefit/risk balance did not support the approval of JZP-6 for the treatment of with the currently proposed Risk Evaluation Mitigation Strategy (REMS).

21 Aug 2010

Long-term exercise reduces chronic musculoskeletal pain: Research

Since returning home, some 100,000 veterans from the first Gulf War have reported chronic musculoskeletal pain (CMP) similar to fibromyalgia, and a new study in The Journal of Pain, published by the American Pain Society, shows that acute exercise can exacerbate the pain but long-term exercise has the opposite outcome and reduces it.

21 Aug 2010

FDA Advisory Committee votes in favor of expanding pain indications for Eli Lilly's Cymbalta

The U.S. Food and Drug Administration (FDA) Anesthetic and Life Support Drugs Advisory Committee voted 8-6 in favor of expanding the pain indications for Eli Lilly and Company's (NYSE: LLY) Cymbalta® (duloxetine HCl) to a broader pain population that will be further defined by the FDA, if approved.

20 Aug 2010

Chelsea Therapeutics announces new investigator to conduct phase II clinical study of Droxidopa

Chelsea Therapeutics International, Ltd. announced that a new investigator-led phase II clinical study of Droxidopa, an oral synthetic precursor of norepinephrine, has been initiated in chronic fatigue syndrome (CFS).

20 Aug 2010

Deconstruction of biomedical research on pain will improve diagnosis, treatment of chronic pain sufferers

Is the science of diagnosing pain causing a number of pain sufferers to defend their honor? Research out of the University of Cincinnati is examining the diagnosis of pain that evades scientific testing, and the additional emotional suffering that can result for the patient.

17 Aug 2010

Adeona reports $979,782 net income for second-quarter 2010 vs. $879,550 net loss for same period in 2009

Adeona Pharmaceuticals, Inc. announced its second quarter 2010 financial results and recent achievements.

16 Aug 2010

Chronic pain affects higher proportion of women than men: Research

Women experience chronic pain longer, more intensely and more often than men, according to a psychologist who works with both men and women dealing with diseases and conditions that leave them suffering.

13 Aug 2010

Jazz Pharmaceuticals second-quarter net product sales increase 49% to $39.5 million

Jazz Pharmaceuticals, Inc. announced financial results for the second quarter ended June 30, 2010 and updated financial guidance for 2010. The company's updated financial guidance reflects higher expected sales of XYREM® (sodium oxybate) and the effects of recent financing activities.

11 Aug 2010

Intrinsic brain connectivity in fibromyalgia associated with chronic pain intensity

A recent study from researchers at Massachusetts General Hospital and University of Michigan provides the first direct evidence of linkage between elevated intrinsic (resting-state) brain connectivity and spontaneous pain intensity in patients with fibromyalgia (FM). This research shows an interaction of multiple brain networks, offering greater understanding of how pain arises. Details of the study appear online and in the August issue of Arthritis & Rheumatism, a journal published by Wiley-Blackwell on behalf of the American College of Rheumatology.

30 Jul 2010

Resting brain activity associated with spontaneous fibromyalgia pain

29 Jul 2010

POA releases consensus statement on CIRS-WDB

Policyholders of America released a consensus statement written by treating physicians and researchers in the field on the mechanism and treatment of illness found in people sickened by exposure to water-damaged buildings. This illness has been the subject of heated debate that has resulted in harsh allegations being lobbed at patients by experts hired by industry to cast doubt on the legitimacy of the illness.

28 Jul 2010

Forest Laboratories reports first-quarter diluted EPS of $0.39

Forest Laboratories, Inc., an international pharmaceutical manufacturer and marketer, announced that diluted earnings per share equaled $0.39 in the first quarter of fiscal 2011. Excluding the charge related to the United States Department of Justice investigations described below, and a charge of $50.0 million, or $0.17 per share net of tax, for a new product licensing fee, non-GAAP earnings per share for the first fiscal quarter were $0.95 per share.

20 Jul 2010

Obesity, chronic pain linked to family history, mood disorders: Study

Though it is well known obese individuals have a high incidence of persistent pain problems, a new study in The Journal of Pain, published by the American Pain Society, reports that comorbid obesity and pain also are linked to family history and mood disorders.

20 Jul 2010

Adeona completes $1 million equity financing and provides update on Zinthionein ZC clinical study

Adeona Pharmaceuticals, Inc., announced today that on July 6, 2010, it completed an equity financing of $1 million with a single institutional investor, Seaside 88, L.P. The financing involved the sale of 1,212,121 registered shares of common stock and no warrants. Enclave Capital served as placement agent and will receive a 7% cash commission and 5-year warrants to acquire 60,606 shares of Adeona at $1.32 per share. The use of proceeds is intended for general corporate purposes.

6 Jul 2010

Chelsea reports positive outcome from DMC review of droxidopa Phase II trial in fibromyalgia

Chelsea Therapeutics International, Ltd. announced the completion and favorable outcome of an independent Data Monitoring Committee (DMC) review of the safety and efficacy data from approximately half the target enrollment in Chelsea's Phase II trial of droxidopa in fibromyalgia.

2 Jul 2010

Chelsea completes enrollment in Northera Phase III Study 301 for neurogenic orthostatic hypotension

Chelsea Therapeutics International, Ltd. has successfully reached its target enrollment of 150 patients in its Northera™ (Droxidopa) pivotal Phase III Study 301 for the treatment of symptomatic, neurogenic orthostatic hypotension (NOH). Results from the trial are expected in September 2010 and the full registration program is on track to initiate a new drug application (NDA) in the first half of 2011.

30 Jun 2010

Fibromyalgia News and Research

Latest Fibromyalgia News and Research

Latest achievements in brain research and treatment for mental disorders

23rd European College of Neuropsychopharmacology Congress to be held 28 Aug - 1 Sep 2010 in Amsterdam

Vitamin D2 in AbM mushroom can neutralize oxidative stress: Research

National Fibromyalgia Association, RemedyMD partner to build fibromyalgia research registry

Jazz Pharmaceuticals disappointed with FDA Advisory Committee recommendation for JZP-6 in fibromyalgia

Long-term exercise reduces chronic musculoskeletal pain: Research

FDA Advisory Committee votes in favor of expanding pain indications for Eli Lilly's Cymbalta

Chelsea Therapeutics announces new investigator to conduct phase II clinical study of Droxidopa

Deconstruction of biomedical research on pain will improve diagnosis, treatment of chronic pain sufferers

Adeona reports $979,782 net income for second-quarter 2010 vs. $879,550 net loss for same period in 2009

Chronic pain affects higher proportion of women than men: Research

Jazz Pharmaceuticals second-quarter net product sales increase 49% to $39.5 million

Intrinsic brain connectivity in fibromyalgia associated with chronic pain intensity

Resting brain activity associated with spontaneous fibromyalgia pain

POA releases consensus statement on CIRS-WDB

Forest Laboratories reports first-quarter diluted EPS of $0.39

Obesity, chronic pain linked to family history, mood disorders: Study

Adeona completes $1 million equity financing and provides update on Zinthionein ZC clinical study

Chelsea reports positive outcome from DMC review of droxidopa Phase II trial in fibromyalgia

Chelsea completes enrollment in Northera Phase III Study 301 for neurogenic orthostatic hypotension

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Fibromyalgia News and Research

Latest Fibromyalgia News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in